CellMed AG is a
BTG International group company
Aesthetic Programme: MDF-100 and M-Gel
This cosmetic dermatology programme is focused on the dermal filler market segment. Dermal filler products address the market for the cosmetic treatment of facial wrinkles and for skin augmentation and they are injected via a non-surgical procedure. Our aim is that our technology will provide a next-generation material to improve on the products that make up the $1bn US market.
MDF-100: microbead formulation of our biopolymer being developed for the aesthetic market.
M-Gel: solution formulation of our biopolymer being developed for the aesthetic market.
AlyCM18 Enzyme: being developed to allow for the rapid degradation of the biopolymer in instances when required .
